AC-KPV-NH2

What it is?

AC-KPV-NH2 is the smallest biologically active fragment of α-MSH (alpha-melanocyte stimulating hormone), studied for its role in inflammation-modulating signalling. It is positioned for protocols where inflammatory tone, immune balance, and tissue-calming pathways are primary endpoints—particularly in skin and barrier-focused frameworks.

Dripfy Advantage

• Receptor engagement: Interacts with melanocortin receptors implicated in inflammation-control signalling pathways.
• Cytokine modulation: Positioned to reduce pro-inflammatory cytokine signalling, supporting a more regulated inflammatory microenvironment.
• Barrier and tissue-calming orientation: Frequently positioned for tissue-calming endpoints where barrier integrity and local inflammation are tracked.
• Immune balance support: Often framed as supporting immune equilibrium—modulating excessive inflammatory signalling rather than blunt suppression.

Clinical Applications & Therapeutic Potential

• Inflammation-control frameworks: Potential support for improved inflammatory marker profiles in targeted tissue models (context-dependent).
• Inflammatory skin-condition endpoints: Positioned for skin-calming and barrier-support endpoints where inflammation is a central driver.
• Immune equilibrium outcomes: Potential support for balanced immune signalling and tolerance–vigilance stability markers.
• Localised protocol utility: Often selected for protocols focused on local inflammation control and tissue comfort endpoints.

Composition & Formulation

• Peptide Content: 10 mg KPV peptide
• Vehicle: Proprietary pH-balanced buffer solution
• Delivery System: Pre-filled, multi-dose, closed-system pen
• Total Volume: 3 mL
• Purity: ≥99% by HPLC/MS